Actively Recruiting
Allergy Delabeling in Antibiotic Stewardship - Intervention
Led by Ebbing Lautenbach · Updated on 2026-04-22
3800
Participants Needed
1
Research Sites
184 weeks
Total Duration
On this page
Sponsors
E
Ebbing Lautenbach
Lead Sponsor
U
University of Utah
Collaborating Sponsor
AI-Summary
What this Trial Is About
The overall goal of the RENEW-IN intervention is to assess the impact of a BL allergy delabeling intervention on antibiotic use and clinical outcomes in patients with a hematologic malignancy.
CONDITIONS
Official Title
Allergy Delabeling in Antibiotic Stewardship - Intervention
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with a hematologic malignancy (including Hodgkin and non-Hodgkin lymphoma, leukemia, or myeloma) admitted to an inpatient oncology service
- Reported history of a beta-lactam allergy (penicillin, cephalosporin, or carbapenem)
You will not qualify if you...
- History of severe cutaneous adverse reactions
- History of Stevens-Johnson syndrome
- History of toxic epidermal necrolysis
- History of drug-induced exfoliative dermatitis
- History of drug reaction with eosinophilia and systemic symptoms
- History of acute generalized exanthematous pustulosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
E
Ebbing Lautenbach, MD,MPH,MSCE
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here